Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ.

Neurology. 2003 Jan 14;60(1):44-51.

PMID:
12525716
2.

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.

Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sørensen P.

J Neurol Neurosurg Psychiatry. 2004 May;75(5):706-10.

3.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators..

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
4.
5.

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group..

Neurology. 2001 Jun 12;56(11):1496-504.

PMID:
11402106
6.

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.

Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.

Mult Scler. 2009 Oct;15(10):1195-205. doi: 10.1177/1352458509106937.

PMID:
19797261
7.

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.

Li DK, Zhao GJ, Paty DW; University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group..

Neurology. 2001 Jun 12;56(11):1505-13.

PMID:
11402107
8.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.

Mult Scler. 2009 Aug;15(8):965-76. doi: 10.1177/1352458509105229.

PMID:
19465443
9.

Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.

Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.

J Neurol. 2003 Sep;250(9):1037-43.

PMID:
14504963
10.

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A; Avonex CIDP Study Group..

Neurology. 2010 Feb 23;74(8):651-7. doi: 10.1212/WNL.0b013e3181d1a862.

PMID:
20177118
12.

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS..

Neurology. 2004 Nov 23;63(10):1788-95.

PMID:
15557491
13.
14.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
15.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

PMID:
23744561
16.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M; Independent Comparison of Interferon (INCOMIN) Trial Study Group..

Lancet. 2002 Apr 27;359(9316):1453-60.

PMID:
11988242
17.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators..

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 .

PMID:
18315940
19.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
20.

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH; European Study Group on Interferon Beta-1b in Secondary Progressive MS..

Neurology. 2001 Dec 26;57(12):2191-7.

PMID:
11756596

Supplemental Content

Support Center